A Phase 3 interventional study of THDB0206 and Insulin Lispro in Type 1 Diabetes, sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-15.
Sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Diabetes Mellitus, Type 1 with a site in China — 42 open to participants now, 45 under way, 3 of them phase 3. Diabetes Mellitus, Type 1 · China.
Among the 103 studies in Diabetes Mellitus, Type 1 with a site in China, this one is the 4th largest by enrollment of the 83 interventional ones that give a count, is one of 8 that started in 2022, is one of 12 in phase 3, and was the 92nd registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →42 of the 103 studies in Diabetes Mellitus, Type 1 with a site in China are open now. Recruiting first, the newest first:
SiBionics, Co, Ltd · Sites in China
Ages 18+
Nanjing Medical University · Sites in China
Ages 18–65
Shanghai Zhongshan Hospital · Sites in China
Ages 18–40
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 14–65
Nanjing Medical University · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 18 · Phase 3 13 · Phase 4 13
First in 2003; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 550 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 50 across the 83 interventional studies, 500 across the 20 observational. Of the 33 that completed or were terminated, 10 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 103 have an industry lead sponsor. The 10 most frequent:
Tonghua Dongbao Pharmaceutical Co.,Ltd is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Tonghua Dongbao Pharmaceutical Co.,Ltd has 1 study filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
10 of the studies in Diabetes Mellitus, Type 1 with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708780The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolImmunotherapy with Autologous Tregs in T1DM | 2026-12 |
| NCT06496412Second Xiangya Hospital of Central South UniversitySafety and Efficacy of Fecal Microbiota Transplantation on Cognitive Function in T1DM | 2026-12-30 |
| NCT06198725Children's Hospital of Fudan UniversityIntervention for Children With Type 1 Diabetes Targeting Gut Microbes | 2026-12-31 |
| NCT07051564Zibo Central HospitalClinical Study on the Treatment of Type 1 Diabetes With CNK-UT009 Cell Injection | 2026-12-31 |
| NCT05294653Shanghai Jiao Tong University School of MedicineAtherosclerotic Cardiovascular Risk in Childhood and Teen-age Onset Diabetes | 2027-01-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 103 studies in Diabetes Mellitus, Type 1 with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 26-week randomized, open-label, multicenter, active-controlled parallel group trial. The purpose of this study is to compare efficacy and safety of THDB0206 injection with insulin lispro injection combined with insulin glargine injection U-100 in Chinese participants with T1DM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Stable insulin regimen ≥3 months prior to screening (no change in insulin class), with or without metformin or alpha-glucosidase inhibitors; willing to follow multiple daily injections:
Exclusion Criteria:
Hepatic or renal impairment at screening (per local laboratory reference ranges):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: THDB0206 · Drug: Insulin Glargine
Drug: Insulin Lispro · Drug: Insulin Glargine
Subcutaneous THDB0206 three times daily, with individualized dose adjustment.
Subcutaneous insulin lispro three times daily, with individualized dose adjustment.
Subcutaneous insulin glargine once daily, with individualized dose adjustment.
Change from Baseline in HbA1c at Week 26
Time frame: Week 26
Change from Baseline in 1-hour Postprandial Glucose (PPG) Excursion at Week 26
Time frame: Week 26
Change from Baseline in 2-hour Postprandial Glucose (PPG) Excursion at Week 26
Time frame: Week 26
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2022 to primary completion in Jan 2025, 33 months.
Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 33 months is above that.
Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: THDB0206
Tonghua Dongbao Pharmaceutical Co.,Ltd